MetaVia Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| MTVA | POXEL.PA | ET80.F | ADXN | BMEA | MGX | |
|---|---|---|---|---|---|---|
| Market cap | 8.83M | 10.65M | 5.30M | 5.33M | 44.24M | 29.84M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | — | 0.2 | — | -60.9 | -0.7 | -0.4 |
| Price/book | 1.3 | -0.1 | 0.4 | 1.4 | 3.7 | 0.3 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −85.67% | −32.33% | −16.51% | −65.26% | −52.92% | −64.41% |
| Today | +6.35% | +0.63% | +0.95% | +1.27% | −1.91% | +3.95% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All MTVA news ›MetaVia to Present Phase 1 Clinical Trial Data for DA-1726 in Oral Presentation at the Precision Liver Symposium 2026
Title: DA-1726, a Dual GLP-1 and Glucagon Receptor Agonist, Leads to Significant Reduction in MRI-PDFF and Weight Loss with Relative Preservation of Lean Mass: A Randomized Placebo-Controlled Trial Presenting Author: Sarah Browne, M.D.,…
MetaVia Appoints Seasoned Clinical Development Executive Sarah Browne, M.D., as Chief Medical Officer
PR Newswire Brings Extensive Experience Leading Liver and Metabolic Disease Drug Development Programs, Including MASH, and Successfully Advancing Therapies Through Phase 2 and Into Phase 3 Developme
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- prnewswire.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 1 articles, not a forecast.